Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Altimmune (ALT) over the last 17 years, with Q3 2025 value amounting to $27.1 million.

  • Altimmune's Total Non-Current Liabilities rose 36248.93% to $27.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.1 million, marking a year-over-year increase of 36248.93%. This contributed to the annual value of $5.3 million for FY2024, which is 2119.15% up from last year.
  • As of Q3 2025, Altimmune's Total Non-Current Liabilities stood at $27.1 million, which was up 36248.93% from $23.6 million recorded in Q2 2025.
  • Altimmune's Total Non-Current Liabilities' 5-year high stood at $27.1 million during Q3 2025, with a 5-year trough of $4.1 million in Q1 2024.
  • Over the past 5 years, Altimmune's median Total Non-Current Liabilities value was $10.7 million (recorded in 2021), while the average stood at $11.9 million.
  • As far as peak fluctuations go, Altimmune's Total Non-Current Liabilities tumbled by 6641.5% in 2022, and later skyrocketed by 36248.93% in 2025.
  • Altimmune's Total Non-Current Liabilities (Quarter) stood at $13.6 million in 2021, then tumbled by 66.41% to $4.6 million in 2022, then decreased by 3.99% to $4.4 million in 2023, then rose by 21.19% to $5.3 million in 2024, then skyrocketed by 407.52% to $27.1 million in 2025.
  • Its Total Non-Current Liabilities stands at $27.1 million for Q3 2025, versus $23.6 million for Q2 2025 and $5.3 million for Q1 2025.